Wendy Becker Acquires 441 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Wendy Becker acquired 441 shares of GSK stock in a transaction that occurred on Friday, December 19th. The shares were purchased at an average price of GBX 1,809 per share, with a total value of £7,977.69.

GSK Trading Up 0.2%

Shares of LON:GSK opened at GBX 1,814.50 on Wednesday. The stock’s 50-day simple moving average is GBX 1,765.38 and its two-hundred day simple moving average is GBX 1,569.60. The stock has a market capitalization of £73.26 billion, a price-to-earnings ratio of 13.64, a PEG ratio of 1.24 and a beta of 0.31. GSK plc has a 52-week low of GBX 1,242.50 and a 52-week high of GBX 1,853.50. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK) last released its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts expect that GSK plc will post 175.980975 EPS for the current year.

GSK News Roundup

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to sell its U.S. Human Genome Sciences manufacturing unit to Samsung Biologics for roughly $280m — a near‑term cash inflow that can be used to pay down debt, fund R&D or support capital returns; the deal also removes an asset/operational burden from GSK’s footprint, which investors often view as portfolio simplification. Samsung Biologics Boosts U.S. Presence With $280M GSK Facility Deal
• Positive Sentiment: Insider purchases: directors Wendy Becker and Jonathan Symonds bought shares (441 and 1,650 shares at ~GBX 1,809–1,810), signalling management confidence and providing a small psychological and technical bid under the stock. Wendy Becker Acquires 441 Shares of GSK (LON:GSK) Stock
• Neutral Sentiment: The buyer, Samsung Biologics, gains its first U.S. production base — a strategic move for Samsung but largely a reallocation of manufacturing capacity rather than a change to GSK’s core commercial portfolio; impact on GSK cashflow is immediate, but operational effects are limited. Samsung Biologics buys GSK’s Human Genome Sciences unit to expand US biologics manufacturing
• Negative Sentiment: GSK reached a pricing agreement with the U.S. government to cut certain drug prices — this creates downside risk to future revenue and margins for any covered products; the long‑term impact depends on scope, which drugs are included and how broadly the terms apply. GSK strikes deal to cut drug prices with US government

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on GSK shares. JPMorgan Chase & Co. boosted their price objective on shares of GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research report on Friday, November 7th. Berenberg Bank boosted their price target on GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a report on Monday, November 24th. Shore Capital restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Monday, October 20th. Finally, Jefferies Financial Group lifted their price objective on GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research report on Monday, November 3rd. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of GBX 1,762.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.